Device Trial Radar · NCT03973866
Alfapump® System in the Treatment of Refractory or Recurrent Ascites (POSEIDON Study)
Last checked: Nov 19, 2026Latest source record: Dec 1, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
110
Actual
Start
Sep 16, 2019
Primary completion
Mar 30, 2024
Study completion Jun 30, 2024
Sponsor
- Lead sponsor
- Sequana Medical N.V.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Jun 4, 2019
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The POSEIDON study is a multi-center, prospective, single arm, crossover pivotal study enrolling up to 70 pivotal cohort patients and up to 45 additional Roll-in patients with refractory or recurrent ascites at up to 20 sites. Pivotal cohort patients will undergo a 3-month pre-implant observation phase after enrollment, followed by implantation of the alfapump and 24 months of post-implant follow up. An analysis will be conducted to support an application for device approval when a minimum of 40 treated pivotal cohort patients are through 6 months.
Conditions
- Ascites
Interventions
AlfapumpDevice
Implantation of alfapump
Primary outcomes
What the sponsor says the trial is designed to measure.
- Per-patient ratio of post-implant to pre-implant with respect to average monthly number of therapeutic paracentesisTime frame: Comparing data from the post-implant 3-month observation period to data from the pre-implant 3-month observation period:
- Proportion of patients with at least 50% reduction in number of therapeutic paracenteses from the pre-observation period to post-observation periodTime frame: Comparing data from the post-implant 3-month observation period to data from the pre-implant 3-month observation period
- Combined rate of open surgical reintervention due to pump system related adverse event or to restore pump functionality, pump explant due to pump system related adverse event, or pump system related deathTime frame: from time of pump implant through 6 months post-implant
Locations
15 sites in 2 countries. Site status is shown where the registry gives one.
Mayo Clinic (Arizona)
Phoenix, Arizona
Cedars-Sinai Comprehensive Transplant Center
Los Angeles, California
University of Massachusetts Memorial Medical Center
Worcester, Massachusetts
12 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.